Key result
Low-molecular-weight heparins and new antiplatelet therapies are emerging as potentially superior alternatives to traditional anticoagulants for percutaneous coronary interventions.
Why the study?
Do low-molecular-weight heparins and new antiplatelet therapies improve outcomes compared to unfractionated heparin and aspirin in patients undergoing percutaneous coronary interventions?
Population
Patients undergoing percutaneous coronary interventions and those with unstable angina
Comparison
Low-molecular-weight heparin and new… vs Unfractionated heparin and standard aspirin…
Design
Review
Authors
Loading...
May support refined antithrombotic regimens in PCI; leaves open confirmation via dedicated randomized trials.
Do low-molecular-weight heparins and new antiplatelet therapies improve outcomes compared to unfractionated heparin and aspirin in patients undergoing percutaneous coronary interventions?
Low-molecular-weight heparins and novel antiplatelet agents offer potential advantages over traditional unfractionated heparin and aspirin in improving outcomes for patients undergoing percutaneous coronary interventions.
Ezra Deutsch (1999) conducted a review in Percutaneous coronary interventions. Low-molecular-weight heparin and antiplatelet therapies vs. Unfractionated heparin and traditional antiplatelet therapies was evaluated. Low-molecular-weight heparins and new antiplatelet therapies are emerging as potentially superior alternatives to traditional anticoagulants for percutaneous coronary interventions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: